NEW YORK--(BUSINESS WIRE)--ENB Therapeutics, Inc., a biotechnology company pioneering a new and differentiated class of therapeutics targeting the endothelin B receptor (ETBR) inhibitor, today ...
NEW YORK--(BUSINESS WIRE)--ENB Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced top-line results from the dual combination arm of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results